help button home button Am J Pathol ASIP MEMBERSHIP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sitara, D.
Right arrow Articles by Lanske, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sitara, D.
Right arrow Articles by Lanske, B.
(American Journal of Pathology. 2006;169:2161-2170.)
© 2006 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2006.060329

Genetic Ablation of Vitamin D Activation Pathway Reverses Biochemical and Skeletal Anomalies in Fgf-23-Null Animals

Despina Sitara*, Mohammed S. Razzaque*, René St-Arnaud{dagger}, Wei Huang*, Takashi Taguchi{ddagger}, Reinhold G. Erben§ and Beate Lanske*

From the Department of Developmental Biology,* Harvard School of Dental Medicine, Boston, Massachusetts; the Genetics Unit,{dagger} Shriners Hospital, Montreal, Quebec, Canada; the Department of Pathology,{ddagger} Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; and the Department of Natural Sciences,§ University of Veterinary Medicine, Vienna, Austria

Fibroblast growth factor-23 (FGF-23) is one of the circulating phosphaturic factors associated with renal phosphate wasting. Fgf-23–/– animals show extremely high serum levels of phosphate and 1,25-dihydroxyvitamin D3, along with abnormal bone mineralization and soft tissue calcifications. To determine the role of vitamin D in mediating altered phosphate homeostasis and skeletogenesis in the Fgf-23–/– mice, we generated mice lacking both the Fgf-23 and 1{alpha}-hydroxylase genes (Fgf-23–/–/1{alpha}(OH)ase–/–). In the current study, we have identified the cellular source of Fgf-23 in adult mice. In addition, loss of vitamin D activities from Fgf-23–/– mice reverses the severe hyperphosphatemia to hypophosphatemia, attributable to increased urinary phosphate wasting in Fgf-23–/–/1{alpha}(OH)ase–/– mice, possibly as a consequence of decreased expression of NaPi2a. Ablation of vitamin D from Fgf-23–/– mice resulted in further reduction of total bone mineral content and bone mineral density and reversed ectopic calcification of skeleton and soft tissues, suggesting that abnormal mineral ion homeostasis and impaired skeletogenesis in Fgf-23–/– mice are mediated through enhanced vitamin D activities. In conclusion, using genetic manipulation studies, we have provided evidence for an in vivo inverse correlation between Fgf-23 and vitamin D activities and for the severe skeletal and soft tissue abnormalities of Fgf-23–/– mice being mediated through vitamin D.





This article has been cited by other articles:


Home page
PhysiologyHome page
T. Berndt and R. Kumar
Novel Mechanisms in the Regulation of Phosphorus Homeostasis
Physiology, February 1, 2009; 24(1): 17 - 25.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
T. Nakatani, B. Sarraj, M. Ohnishi, M. J. Densmore, T. Taguchi, R. Goetz, M. Mohammadi, B. Lanske, and M. S. Razzaque
In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis
FASEB J, February 1, 2009; 23(2): 433 - 441.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
X. Bai, Q. Dinghong, D. Miao, D. Goltzman, and A. C. Karaplis
Klotho ablation converts the biochemical and skeletal alterations in FGF23 (R176Q) transgenic mice to a Klotho-deficient phenotype
Am J Physiol Endocrinol Metab, January 1, 2009; 296(1): E79 - E88.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
R. Bouillon, G. Carmeliet, L. Verlinden, E. van Etten, A. Verstuyf, H. F. Luderer, L. Lieben, C. Mathieu, and M. Demay
Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice
Endocr. Rev., October 1, 2008; 29(6): 726 - 776.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
O. M. Gutierrez, M. Mannstadt, T. Isakova, J. A. Rauh-Hain, H. Tamez, A. Shah, K. Smith, H. Lee, R. Thadhani, H. Juppner, et al.
Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis
N. Engl. J. Med., August 7, 2008; 359(6): 584 - 592.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
M. S Razzaque and B. Lanske
The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis
J. Endocrinol., July 1, 2007; 194(1): 1 - 10.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
J. R. Stubbs, S. Liu, W. Tang, J. Zhou, Y. Wang, X. Yao, and L. D. Quarles
Role of Hyperphosphatemia and 1,25-Dihydroxyvitamin D in Vascular Calcification and Mortality in Fibroblastic Growth Factor 23 Null Mice
J. Am. Soc. Nephrol., July 1, 2007; 18(7): 2116 - 2124.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Khosravi, C. M. Cutler, M. H. Kelly, R. Chang, R. E. Royal, R. M. Sherry, F. M. Wodajo, N. S. Fedarko, and M. T. Collins
Determination of the Elimination Half-Life of Fibroblast Growth Factor-23
J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2374 - 2377.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
S. Liu and L. D. Quarles
How Fibroblast Growth Factor 23 Works
J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1637 - 1647.
[Abstract] [Full Text] [PDF]


Home page
IBMS BoneKEyHome page
G. J. Strewler
Bone Talk: Klotho and FGF23 Signaling
IBMS BoneKEy, December 1, 2006; 3(12): 36 - 40.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society for Investigative Pathology.